US-based biotechnology company Nona Biosciences has partnered with Kodiak Sciences to discover novel multi-target antibodies to treat ophthalmic diseases.
The collaboration will leverage Nona’s unique Harbour Mice fully human antibody platform which generates antibodies in two heavy and two light chains (H2L2) format.
The platform also generates antibodies in heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanisation.
Under the partnership, Kodiak will obtain the rights to both the H2L2 and HCAb Harbour Mice platforms in multiple programs to discover and develop therapeutic antibodies.
Kodiak Sciences chairman and CEO Victor Perlroth said: “Retinal diseases involve a complex etiology, so advancing more effective therapies will require targeting multiple pathways at once.
“We are thrilled to announce our partnership with Nona Biosciences, leveraging their advanced Harbour Mice platforms and robust expertise in antibody discovery.
“This collaboration will accelerate our mission to create next-generation biotherapeutics, combining our strengths to bring innovative treatments to patients in need.”
Kodiak is a biopharmaceutical company engaged in researching, developing, and marketing advanced therapeutics to treat a broad spectrum of retinal diseases.
Nona provides drug delivery solutions, ranging from target validation and antibody discovery through preclinical research.
Its HCAb Harbour Mice platform is said to produce fully human-heavy chain-only antibodies that are nearly half the size of conventional IgGs, delivering significant advantages.
Nona Biosciences chairman Jingsong Wang said: “We are pleased to collaborate with Kodiak Sciences to advance novel antibody therapies for ophthalmic diseases. This agreement further validates our proprietary Harbour Mice technology platform.
“With Nona’s industry-leading technology and expertise, we look forward to supporting Kodiak Sciences in accelerating their next-generation therapeutic antibody development and bringing more innovative therapies to patients.”
Earlier this year, Nona entered into a collaboration agreement with preclinical-stage biotechnology company Alaya.bio to advance the development of CAR-T cell therapies.
